spio contrast agent  (Bayer Schering Pharma)

Journal: Frontiers in Medicine

Article Title: SPIO-enhanced MRI for differentiating metastatic from reactive hyperplastic lymph nodes in breast cancer: diagnostic performance and association with VEGF-C expression

doi: 10.3389/fmed.2026.1800084

Figure Lengend Snippet: Representative SPIO-enhanced MRI appearances of lymph nodes. (A) Post-SPIO T2*-weighted image of a reactive hyperplastic axillary lymph node (arrow) demonstrating marked signal loss, consistent with macrophage-mediated iron uptake. (B) Post-SPIO T2*-weighted image of a metastatic axillary lymph node (arrow) showing preserved signal intensity, consistent with reduced iron uptake due to tumor cell replacement of normal lymphoid tissue. Field strength: 3.0 T; imaging performed 12 h after intravenous administration of SPIO (Resovist, 0.2 mL/kg).

Article Snippet: The SPIO contrast agent (Resovist; Bayer Schering Pharma; ferucarbotran) was administered intravenously at a dose of 0.2 mL/kg (approximately 0.56 mg Fe/kg), followed by a saline flush.

Techniques: Imaging

Journal: Disease Models & Mechanisms

Article Title: High- and ultrahigh-field magnetic resonance imaging of naïve, injured and scarred vocal fold mucosae in rats

doi: 10.1242/dmm.026526

Figure Lengend Snippet: Superparamagnetic iron oxide (SPIO) contrast enhancement of acute vocal fold injury. (A) T2- and T2*-weighted (T2W, T2*W) coronal images of the rat abdomen and neck, acquired in vivo at 4.7 T with and without intravenous SPIO contrast enhancement. Red asterisks indicate livers, red arrows indicate larynges. (B) T2W axial and coronal images of the rat larynx, 5 days following right-sided vocal fold mucosal injury. Images were acquired ex vivo at 4.7 T, with and without (pre-explant) intravenous SPIO contrast enhancement. Red arrows indicate hypointense mucosal lesions. (C) Pseudocolored volume renders of the vocal fold mucosal lesions shown in B. Lesions are red; thyroid (brown), cricoid (green) and arytenoid (cyan) cartilages are shown for anatomic orientation. (D) Effect of contrast enhancement on vocal fold mucosal lesion volume (mean±s.e.m.); n.s., no significant difference ( P >0.01), calculated using a Student's t -test. (E) H&E-, Prussian Blue- and CD68-stained vocal fold coronal sections, 5 days following mucosal injury. Black arrows indicate blood (red) and hemosiderin (brown) in the H&E-stained sections and ferric iron (blue) in the Prussian Blue-stained sections; white arrows indicate CD68 + cells (green) in the immunosections (nuclei are counterstained blue). Scale bars: 100 µm. Data represent n =5 animals per experimental condition in A-E, with the exception of the injury+SPIO images and render in panels B and C; these data represent n =2/5 animals in which contrast enhancement was associated with larger lesion volumes. R, right; L, left.

Article Snippet: To reduce T2 relaxation time and evaluate its effect on tissue contrast, we injected a subset of rats in the 5 day post-injury group with intravenous SPIO contrast agent [200 μmol Fe/kg Ferex (∼5 nm iron core size, ∼50-150 nm colloidal matrix size), BioPal, Worcester, MA], 24 h before image acquisition.

Techniques: In Vivo, Ex Vivo, Staining